Brief reports. Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae
|
|
- Damon Payne
- 6 years ago
- Views:
Transcription
1 Journal of Antimicrobial Chemotherapy (1997) 40, Brief reports JAC Decreased susceptibility to imipenem among penicillin-resistant Streptococcus pneumoniae Andreas Pikis a *, Jacob A. Donkersloot b, Shama Akram c, Jerry M. Keith b, Joseph M. Campos d and William J. Rodriguez a a Department of Infectious Diseases, Children s National Medical Center, Washington, DC; b Laboratory of Microbial Ecology, National Institute of Dental Research, National Institutes of Health, Bethesda MD; c Microbiology Research, The Research Foundation, Children s National Medical Center, Washington, DC; d Department of Laboratory Medicine, Children s National Medical Center, and the Departments of Paediatrics, Pathology and Microbiology/Immunology, George Washington University Medical Center, Washington, DC, USA We assessed the antimicrobial susceptibilities of 59 penicillin-intermediate or penicillinresistant pneumococci. All strains were susceptible to vancomycin and rifampicin. The frequency of strains with decreased susceptibility to cefotaxime, chloramphenicol, imipenem and meropenem was 15, 31, 47 and 49% respectively. The high percentage of penicillinintermediate or penicillin-resistant Streptococcus pneumoniae with decreased susceptibility to third-generation cephalosporins, chloramphenicol and carbapenems limits the therapeutic options for the treatment of invasive pneumococcal infections and particularly of meningitis. Introduction Streptococcus pneumoniae remains a significant cause of morbidity and mortality in all age groups. It is a major cause of otitis media, sinusitis, pneumonia, bacteraemia and meningitis. The increasing frequency of pneumococcal strains resistant to penicillin and other antibiotics has raised significant concerns regarding the management of patients with pneumococcal infections, particularly meningitis. 1 In areas with a high prevalence of penicillin- and cephalosporin-resistant pneumococci the combination of vancomycin and a third-generation cephalosporin is currently recommended as the initial empirical antibiotic therapy in children with suspected pneumococcal meningitis. 1 Imipenem has been shown to be very effective in vitro and in experimental meningitis against penicillinresistant pneumococci. 2 Consequently in areas with a high prevalence of penicillin- and cephalosporin-resistant pneumococci some investigators have proposed imipenem as an alternative for the empirical treatment of patients with suspected pneumococcal meningitis. After testing a small number of penicillin-resistant pneumococci, we found that several strains also had decreased susceptibility to various antibiotics including third-generation cephalosporins and the carbapenem imipenem. These findings prompted us to investigate the susceptibility of a larger number of penicillin-resistant pneumococci to imipenem and other antibiotics. Materials and methods This study included 59 S. pneumoniae strains with decreased susceptibility to penicillin (52 were penicillinintermediate and seven penicillin-resistant) recovered from usually sterile body sites. Strains were either isolated by the Clinical Microbiology Laboratory at Children s National Medical Center, Washington, DC, USA, or referred from other hospitals or clinics in the Washington metropolitan area to the Laboratory of Microbiology Research at the same hospital. The identification of S. pneumoniae was based on optochin sensitivity and bile *Corresponding author. Department of Infectious Diseases, Children s National Medical Center, W 3.5, Suite 100, 111 Michigan Avenue, NW, Washington, DC , USA. Tel: ; Fax: The British Society for Antimicrobial Chemotherapy 105
2 A. Pikis et al. solubility. MICs of penicillin and other antimicrobial agents were determined by an agar dilution method with a final inoculum of 10 4 cfu delivered by a Steers Foltz replicator on to Mueller Hinton agar enriched with 3% lysed horse blood and incubated for h at 37 C in a 7% CO 2 atmosphere. The MIC was defined as the lowest concentration of the antibiotic that inhibited visible growth. Strains were defined as susceptible to penicillin when the MIC was 0.06 mg/l, intermediate when the MIC was between 0.1 and 1 mg/l, and resistant when the MIC was 2 mg/l. The following antimicrobial agents were tested: imipenem (Merck Sharp and Dohme, Rahway, NJ, USA), meropenem (Zeneca Pharmaceutical Group, Wilmington, DE, USA), cefotaxime, chloramphenicol, penicillin G, rifampicin and vancomycin (US Pharmacopeial Convention, Inc., Rockville, MD, USA). Serotyping was performed on the basis of capsular swelling (Quellung reaction) with type-specific pneumococcal antisera. The Danish system of nomenclature was used. Thirteen randomly selected pneumococcal strains were submitted to Merck Research Laboratories (Rahway, NJ, USA) for independent imipenem MIC determination. Susceptibility testing for these isolates was performed with the microtitre broth dilution method using cation-adjusted Mueller Hinton broth with 3% lysed horse blood. Results The susceptibilities of the 59 S. pneumoniae strains to selected antimicrobial agents were determined (Table). As judged by recommended susceptibility breakpoints, all strains were susceptible to vancomycin and rifampicin. On the other hand, 15, 31, 47 and 49% of penicillin-intermediate or penicillin-resistant strains had decreased susceptibility to cefotaxime, chloramphenicol, imipenem and meropenem, respectively. Five of the nine strains with decreased susceptibility to cefotaxime were cefotaximeintermediate and the other four were cefotaxime-resistant. Twenty-eight of the 59 strains exhibited decreased susceptibility to imipenem (all were imipenem-intermediate). MICs of imipenem determined by Merck Research Laboratories for the 13 randomly selected strains confirmed our results. Meropenem MICs ranged from to 1 mg/l (MIC 50 and MIC 90 were 0.25 and 0.5 mg/l, respectively). According to the manufacturer s recommendations for the meropenem MIC susceptibility breakpoint, 29 of our strains had decreased susceptibility. There are at present, no NCCLS or manufacturer s recommendations for further categorizing such strains as intermediate or resistant to meropenem. Twenty-six of the 28 strains with decreased susceptibility to imipenem were serotyped. The serotype distribution was as follows: 23F (eight strains), 6B (seven), 14 (six), 6A (three) and 19F (two). Discussion Until recently, cefotaxime or ceftriaxone alone have been the drugs of choice for the treatment of suspected bacterial meningitis in children and infants beyond the neonatal period. However, resistance and clinical failure of these antimicrobial agents in the treatment of pneumococcal meningitis have been noted during the last few years. 3,4 Of great concern are clinical failures with third-generation cephalosporins not only for infections caused by cephalosporin-resistant strains (MICs 2 mg/l), 3 but also for those caused by cephalosporin-intermediate strains (MICs 1 mg/l). 4 Consequently, in areas in which penicillinresistant strains have been identified, the addition of vancomycin to a third-generation cephalosporin has become the standard treatment of suspected pneumococcal meningitis. Vancomycin is presently the only antibiotic for which no resistant strains have been reported in vitro. Clinical failures with vancomycin have been described in four adult patients from Spain (two of them had penicillin-susceptible Table. Susceptibilities to selected antibiotics of 59 S. pneumoniae isolates with decreased susceptibility to penicillin a Antimicrobial MIC breakpoint agent (mg/l) b MIC range MIC 50 MIC 90 % Susceptible Cefotaxime Chloramphenicol Imipenem Meropenem c Rifampicin Vancomycin a Fifty-two strains were penicillin-intermediate and seven were penicillin-resistant. b As recommended by the National Committee for Clinical Laboratory Standards. 11 c As recommended by the manufacturer. 106
3 S. pneumoniae with decreased susceptibility to imipenem and the other two penicillin-resistant pneumococcal meningitis). 5 In this study vancomycin was used as monotherapy, and the dosages were suboptimal (30 mg/kg/day). Additionally, the concomitant administration of dexamethasone in these patients may have contributed to the poor outcome, although a recent report demonstrated that vancomycin penetrates reliably into the CSF of children with bacterial meningitis despite the concomitant administration of dexamethasone. 6 Other potentially useful drugs in the treatment of pneumococcal meningitis due to strains resistant to penicillin and cefotaxime or ceftriaxone include chloramphenicol, rifampicin and imipenem. The incidence of chloramphenicol resistance noted in this study was 31%. In addition, the bactericidal activity of chloramphenicol against strains which are resistant to penicillin is poor, and clinical failures of pneumococcal meningitis caused by penicillin-resistant strains after treatment with chloramphenicol have been reported. 7 Therefore, chloramphenicol should not be used in suspected or proven penicillin-resistant pneumococcal meningitis. Although the clinical role of rifampicin in the treatment of penicillin-resistant pneumococcal meningitis is not clear, it has often been used as part of therapy. 1 It is very effective i n v i t r o against penicillin-resistant pneumococci. However, the results of in-vitro studies vary when rifampicin is used in combination with other antibiotics. In one study, killing activity by -lactam antibiotics and vancomycin was reduced by the addition of rifampicin. Furthermore, resistance to rifampicin may increase rapidly if widespread use occurs. Previous in-vitro studies of imipenem showed that it is the most effective -lactam antibiotic against penicillinresistant pneumococci and has the best bactericidal activity measured by the time killing curve method. 2 It is noteworthy that in the USA a recent survey involving 13 hospitals from 12 states revealed that only one of 544 S. pneumoniae strains isolated during the period 1 October 1991, to 30 September 1992, was resistant to imipenem. 8 Clinical experience with imipenem is limited because of its propensity to cause seizures. Nevertheless, imipenem has been used successfully in two cases of pneumococcal meningitis caused by penicillin-resistant strains that had failed treatment with other antibiotics including thirdgeneration cephalosporins. 9 We noted that 28 of the 59 (47%) penicillin-intermediate or penicillin-resistant strains had also decreased susceptibility to imipenem. The imipenem-intermediate strains were of seven different serotypes suggesting that resistance to this antibiotic is not limited to a single clone. The high incidence of elevated imipenem MICs is not unique for the Washington, DC, area: similar findings have recently been reported from Canada and Switzerland. Meropenem, a new carbapenem which seems not to have epileptogenic side-effects, has been reported to be very effective in vivo and in experimental meningitis against penicillin-resistant S. pneumoniae. Recent clinical trials showed that meropenem is comparable to cefotaxime in the treatment of bacterial meningitis. 10 But there are no data regarding the clinical use of meropenem against pneumococcal strains with decreased susceptibility to penicillin and third-generation cephalosporins. Several of our strains had meropenem MICs higher than the suggested susceptibility breakpoint. The results of this study indicate that a high percentage of our penicillin-intermediate and penicillin-resistant strains also had decreased susceptibility to carbapenems. The higher in-vitro efficacy we noted with cefotaxime compared with that of carbapenems may be a reflection of the MIC breakpoints selected and the limited clinical experience with the latter. Further knowledge of the pharmacokinetics of meropenem as well as additional clinical experience should help resolve this issue. Until further information is available we believe that in areas in which penicillin-intermediate or penicillin-resistant pneumococci have been identified, suspected cases of pneumococcal meningitis should be treated empirically with vancomycin plus cefotaxime or ceftriaxone with or without rifampicin. Subsequent modification of the treatment should be according to the antibiotic susceptibility of the infecting microorganism. References 1. Schreiber, J. R. & Jacobs, M. R. (1995). Antibiotic-resistant pneumococci. Pediatric Clinics of North America 42, Doit, C. P., Bonacorsi, S. P., Fremaux, A. J., Sissia, G., Cohen, R., Geslin, P. L. et al. (1994). In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Journal of Antimicrobial Chemotherapy 38, Bradley, J. S. & Connor, J. D. (1991). Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatric Infectious Disease Journal 10, Catalán, M. J., Fernández, J. M., Vasquez, A., Varela de Seijas, E., Suárez, A. & Bernaldo de Quirós, J. C. (1994). Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae. Clinical Infectious Diseases 18, Viladrich, P. F., Gudiol, F., Línares, J., Pallarés, R., Sabaté, I., Rufí, G. et al. (1991). Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrobial Agents and Chemotherapy 35, Klugman, K. P., Friedland, I. R. & Bradley, J. S. (1995). Bactericidal activity against cephalosporin-resistant Streptococcus pneu - moniae in cerebrospinal fluid of children with acute bacterial meningitis. Antimicrobial Agents and Chemotherapy 39, Friedland, I. R. & Klugman, K. P. (1992). Failure of chloramphenicol therapy in penicillin-resistant pneumococcal meningitis. Lancet 339, Breiman, R. F., Butler, J. C., Tenover, F. C., Elliott, J. A. & 107
4 A. Pikis et al. Facklam, R. R. (1994). Emergence of drug-resistant pneumococcal infections in the United States. Journal of the American Medical Association 271, Asensi, F., Otero, M. C., Pérez-Tamarit, D., Rodríguez-Escribano, I., Cabedo, J. L., Gresa, S. et al. (1993). Risk/benefit in the treatment of children with imipenem-cilastatin for meningitis caused by penicillin-resistant pneumococcus. Journal of Chemotherapy 5, Klugman, K. P., Dagan, R. & the Meropenem Meningitis Study Group. (1995). Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Antimicrobial Agents and Chemotherapy 39, National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing: Sixth Informational Supplement. Document M100-S6. NCCLS, Villanova, PA. Received 5 August 1996; returned 21 October 1996; revised 13 November 1996; accepted 6 February
5 S. pneumoniae with decreased susceptibility to imipenem 109
JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model
Journal of Antimicrobial Chemotherapy (2000) 46, 981 985 JAC Linezolid against penicillin-sensitive and -resistant pneumococci in the rabbit meningitis model Philippe Cottagnoud a *, Cynthia M. Gerber
More informationESCMID Online Lecture Library. by author
Treatment of community-acquired meningitis including difficult to treat organisms like penicillinresistant pneumococci and guidelines (ID perspective) Stefan Zimmerli, MD Institute for Infectious Diseases
More informationAsian Journal of Pharmacy and Life Science ISSN Vol.3 (1), Jan-March, 2013
PROMISING REGIMEN IDOL FOR MENINGITIS TREATMENT DUE TO S. PNEUMONIA RESISTANT STRAINS Sawati Sharma *1, Parul Sood 1 School of Pharmacy and Emerging Sciences, Baddi University of Emerging Sciences & Technology,
More informationClindamycin Therapy of Experimental Meningitis Caused by Penicillinand Cephalosporin-Resistant Streptococcus pneumoniae
ANTIROBIAL AGENTS AND CHEMOTHERAPY, Jan. 1996, p. 122 126 Vol. 40, No. 1 0066-4804/96/$04.00 0 Copyright 1996, American Society for Microbiology Clindamycin Therapy of Experimental Meningitis Caused by
More informationTel: Fax:
CONCISE COMMUNICATION Bactericidal activity and synergy studies of BAL,a novel pyrrolidinone--ylidenemethyl cephem,tested against streptococci, enterococci and methicillin-resistant staphylococci L. M.
More informationMedical bacteriology Lecture 8. Streptococcal Diseases
Medical bacteriology Lecture 8 Streptococcal Diseases Streptococcus agalactiae Beat haemolytic Lancifield group B Regularly resides in human vagina, pharynx and large inine Can be transferred to infant
More informationExperimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis
Journal of Antimicrobial Chemotherapy (2005) 55, 78 83 doi:10.1093/jac/dkh496 Advance Access publication 16 November 2004 JAC Experimental study of teicoplanin, alone and in combination, in the therapy
More informationagainst Clinical Isolates of Gram-Positive Bacteria
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 366-370 Vol. 37, No. 0066-0/93/00366-05$0.00/0 Copyright 993, American Society for Microbiology In Vitro Activity of CP-99,9, a New Fluoroquinolone,
More informationStreptococcus pneumoniae. Oxacillin 1 µg as screen for beta-lactam resistance
Streptococcus pneumoniae Oxacillin µg as screen for beta-lactam resistance Version 6. June Streptococcus pneumoniae and zone diameter correlates The following histograms present inhibition zone diameter
More informationAnnual Report: Table 1. Antimicrobial Susceptibility Results for 2,488 Isolates of S. pneumoniae Collected Nationally, 2005 MIC (µg/ml)
Streptococcus pneumoniae Annual Report: 5 In 5, a total of, isolates of pneumococci were collected from 59 clinical microbiology laboratories across Canada. Of these, 733 (9.5%) were isolated from blood
More informationReceived 13 April 2003; returned 27 October 2003, revised 15 November 2003; accepted 17 November 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 305 310 DOI: 10.1093/jac/dkh082 Advance Access publication 16 January 2004 Ceftriaxone acts synergistically with levofloxacin in experimental meningitis
More informationEARS Net Report, Quarter
EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased
More informationSynergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci
Journal of Antimicrobial Chemotherapy (78) 4, 53-543 Synergism of penicillin or ampicillin combined with sissomicin or netilmicin against enterococci Chatrchal Watanakunakoni and Cheryl Glotzbecker Infectious
More informationPneumococcal Infections in Trinidad: Patterns of Antimicrobial Susceptibility:
Jpn. J. Infect. Dis., 58, 20-24, 2005 Original Article Pneumococcal Infections in Trinidad: Patterns of Antimicrobial Susceptibility: 1994-2002 Fitzroy A. Orrett* Department of Paraclinical Sciences, Faculty
More informationPrinciples and Practice of Antimicrobial Susceptibility Testing. Microbiology Technical Workshop 25 th September 2013
Principles and Practice of Antimicrobial Susceptibility Testing Microbiology Technical Workshop 25 th September 2013 Scope History Why Perform Antimicrobial Susceptibility Testing? How to Perform an Antimicrobial
More information2 0 hr. 2 hr. 4 hr. 8 hr. 10 hr. 12 hr.14 hr. 16 hr. 18 hr. 20 hr. 22 hr. 24 hr. (time)
Key words I μ μ μ μ μ μ μ μ μ μ μ μ μ μ II Fig. 1. Microdilution plate. The dilution step of the antimicrobial agent is prepared in the -well microplate. Serial twofold dilution were prepared according
More informationPharmacology Week 6 ANTIMICROBIAL AGENTS
Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe
More informationClinical Failure of Ceftriaxone Treatment in a Patient with penicillin Resistant Pneumococcal Meningitis
Bahrain Medical Bulletin, Volume 20, Number 1, March 1998 Clinical Failure of Ceftriaxone Treatment in a Patient with penicillin Resistant Pneumococcal Meningitis M N Hassan, MD, DCH* Rambhala Nagamani,
More informationAntibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice?
Antibiotics in vitro : Which properties do we need to consider for optimizing our therapeutic choice? With the support of Wallonie-Bruxelles-International 1-1 In vitro evaluation of antibiotics : the antibiogram
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Inspections EMEA/CVMP/627/01-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE DEMONSTRATION OF EFFICACY
More informationEuropean Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004
European Antimicrobial Resistance Surveillance System (EARSS) in Scotland: 2004 SECOND ANNUAL REPORT MJ Coyne 1, SJ Dancer 1, G Edwards 2, 3, D Morrison 2. 1 Health Protection Scotland, 2 Scottish MRSA
More informationWhat s new in EUCAST methods?
What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests
More informationEUCAST recommended strains for internal quality control
EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationThe Basics: Using CLSI Antimicrobial Susceptibility Testing Standards
The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information
More informationand Health Sciences, Wayne State University and Detroit Receiving Hospital, Detroit, MI, USA
Journal of Antimicrobial Chemotherapy (2004) 54, Suppl. S1, i7 i15 DOI: 10.1093/jac/dkh313 JAC Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae
More informationEDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update
EDUCATIONAL COMMENTARY - Methicillin-Resistant Staphylococcus aureus: An Update Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain
More informationChapter 51. Clinical Use of Antimicrobial Agents
Chapter 51 Clinical Use of Antimicrobial Agents History of antimicrobial therapy Early 17 th century Cinchona bark was used as an important historical remedy against malaria. 1909 Paul Ehrlich sought a
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/26062
More informationSuggestions for appropriate agents to include in routine antimicrobial susceptibility testing
Suggestions for appropriate agents to include in routine antimicrobial susceptibility testing These suggestions are intended to indicate minimum sets of agents to test routinely in a diagnostic laboratory
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationJAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro
Journal of Antimicrobial Chemotherapy (1997) 39, 713 717 JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro Ian Morrissey* Department of Biosciences, Division of Biochemistry
More informationORIGINAL ARTICLE. influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections.
ORIGINAL ARTICLE Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997 98 I. A. Critchley 1, C. Thornsberry
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Antimicrobial susceptibility of Haemophilus influenzae, Neisseria meningitidis and Streptococcus pneumoniae isolates causing meningitis in the Netherlands 1993-1994
More informationPILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 1996
PILOT STUDY OF THE ANTIMICROBIAL SUSCEPTIBILITY OF SHIGELLA IN NEW ZEALAND IN 996 November 996 by Maggie Brett Antibiotic Reference Laboratory ESR Communicable Disease Centre Porirua CONTENTS Page SUMMARY
More informationBarriers to Intravenous Penicillin Use for Treatment of Nonmeningitis
JCM Accepts, published online ahead of print on 7 July 2010 J. Clin. Microbiol. doi:10.1128/jcm.01012-10 Copyright 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationChildrens Hospital Antibiogram for 2012 (Based on data from 2011)
Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical
More informationAntimicrobial Stewardship Strategy: Antibiograms
Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado
More informationOriginal Article. Ratri Hortiwakul, M.Sc.*, Pantip Chayakul, M.D.*, Natnicha Ingviya, B.Sc.**
Original Article In Vitro Activity of Cefminox and Other β-lactam Antibiotics Against Clinical Isolates of Extended- Spectrum-β-lactamase-Producing Klebsiella pneumoniae and Escherichia coli Ratri Hortiwakul,
More informationEXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING
EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING CHN61: EXTENDED-SPECTRUM BETA-LACTAMASE (ESBL) TESTING 1.1 Introduction A common mechanism of bacterial resistance to beta-lactam antibiotics is the production
More informationChristiane Gaudreau* and Huguette Gilbert
Journal of Antimicrobial Chemotherapy (1997) 39, 707 712 JAC Comparison of disc diffusion and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni subsp. jejuni and Campylobacter
More informationScottish Medicines Consortium
Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationReceived 25 September 2000/Returned for modification 29 April 2001/Accepted 12 July 2001
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2001, p. 3328 3333 Vol. 45, No. 12 0066-4804/01/$04.00 0 DOI: 10.1128/AAC.45.12.3328 3333.2001 Copyright 2001, American Society for Microbiology. All Rights
More informationORIGINAL ARTICLE /j x. Western Reserve University, Cleveland, OH, USA and 3 Wockhardt Research Centre, Aurangabad, India
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.01017.x Activity of the new quinolone WCK 771 against pneumococci P. C. Appelbaum 1, G. A. Pankuch 1, B. Bozdogan 1, G. Lin 1, M. R. Jacobs 2, M. V. Patel 3, S.
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The
More informationAntibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut
Antibiotics: mode of action and mechanisms of resistance. Slides made by Special consultant Henrik Hasman Statens Serum Institut This presentation Definitions needed to discuss antimicrobial resistance
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationMRSA surveillance 2014: Poultry
Vicky Jasson MRSA surveillance 2014: Poultry 1. Introduction In the framework of the FASFC surveillance, a surveillance of MRSA in poultry has been executed in order to determine the prevalence and diversity
More informationInternational Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access.
I J A P B International Journal of Advances in Pharmacy and Biotechnology Vol.3, Issue-2, 2017, 1-7 Research Article Open Access. ISSN: 2454-8375 COMPARISON OF ANTIMICROBIAL ACTIVITY AND MIC OF BRANDED
More informationReceived 17 December 2003; accepted 22 December 2003
Journal of Antimicrobial Chemotherapy (2004) 53, 609 615 DOI: 10.1093/jac/dkh130 Advance Access publication 3 March 2004 In vitro post-antibiotic effect of fluoroquinolones, macrolides, β-lactams, tetracyclines,
More informationEmpiric Treatment of Sepsis. Professor of Clinical Microbiology Department of Microbiology Leicester University U. K.
VOL. 38 NO. 8 CHEMO THERAPY Empiric Treatment of Sepsis Emmerson A M Professor of Clinical Microbiology Department of Microbiology Leicester University U. K. Empiric Treatment of Sepsis The treatment of
More informationENTEROCOCCI. April Abbott Deaconess Health System Evansville, IN
ENTEROCOCCI April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic antimicrobial susceptibility principles and resistance mechanisms for Enterococcus Describe issues surrounding AST
More informationRoutine internal quality control as recommended by EUCAST Version 3.1, valid from
Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus
More informationDoxycycline for strep pneumonia
Doxycycline for strep pneumonia Antibiotic Levofloxacin (Levaquin) 750 mg, 500 mg for the treatment of respiratory, skin, and urinary tract infections, user reviews and ratings. 14-12-1995 John G. Bartlett,
More informationWhy we perform susceptibility testing
22 nd June 2015 Why we perform susceptibility testing Robin A Howe Antimicrobial use in Primary Care Why do we perform AST? Clinical Clinical Prediction Prediction of of Efficacy Efficacy Why do we perform
More informationTowards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST)
Towards Rational International Antibiotic Breakpoints: Actions from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) A report to ISC presented by Paul M. Tulkens representative of
More informationHelp with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST
Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to
More informationKey words : penicillin-resistant Streptococcus pneumoniae,
Key words : penicillin-resistant Streptococcus pneumoniae, respiratory infections Table 1 Subject Table 2 Clinical diagnosis of Streptococcus pneumoniae infections Table 3 Undelying disase of Streptococcus
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More informationResistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints
...PRESENTATIONS... Resistance Among Streptococcus pneumoniae: Patterns, Mechanisms, Interpreting the Breakpoints Angela B. Brueggemann, MS; and Gary V. Doern, PhD Presentation Summary Streptococcus pneumoniae
More informationTest organisms. Approximately 50 unique isolates of S. pneumoniae were tested in each of the five laboratories. They
JOURNAL OF CLNCAL ROBOLOGY, Oct. 199, P. 8-59 Vol. 3, No. 10 0095-1137/9/$0.00+0 Copyright 199, American Society for Microbiology Development of nterpretive Criteria and Quality Control Limits for Broth
More informationShould we test Clostridium difficile for antimicrobial resistance? by author
Should we test Clostridium difficile for antimicrobial resistance? Paola Mastrantonio Department of Infectious Diseases Istituto Superiore di Sanità, Rome,Italy Clostridium difficile infection (CDI) (first
More informationModeling the Emergence of Multidrug Antibiotic Resistance
ISDC 2001 - Atlanta, USA Modeling the Emergence of Multidrug Antibiotic Resistance Jack Homer, Ph.D Homer Consulting James Jorgensen, Ph.D Prof. of Pathology & Medicine Univ. of Texas, San Antonio Kate
More informationJan A. Jacobs* and Ellen E. Stobberingh
Journal of Antimicrobial Chemotherapy (996) 37, 37-375 In-vitro antimicrobial susceptibility of the 'Streptococcus millerv group {Streptococcus anginosus, Streptococcus constellatus and Streptococcus intermedius)
More informationPrinciples of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1
Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali Lec 1 28 Oct 2018 References Lippincott s IIIustrated Reviews / Pharmacology 6 th Edition Katzung and Trevor s Pharmacology / Examination
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationVersion 1.01 (01/10/2016)
CHN58: ANTIMICROBIAL SUSCEPTIBILITY TESTING (CLSI) 1.0 PURPOSE / INTRODUCTION: 1.1 Introduction Antimicrobial susceptibility tests are performed in order to determine whether a pathogen is likely to be
More informationChemotherapy of bacterial infections. Part II. Mechanisms of Resistance. evolution of antimicrobial resistance
Chemotherapy of bacterial infections. Part II. Mechanisms of Resistance evolution of antimicrobial resistance Mechanism of bacterial genetic variability Point mutations may occur in a nucleotide base pair,
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationJ. M. Blondeau*, M. Suter, S. Borsos and the Canadian Antimicrobial Study Group
Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. A, 25 30 JAC Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella
More informationDefining Resistance and Susceptibility: What S, I, and R Mean to You
Defining Resistance and Susceptibility: What S, I, and R Mean to You Michael D. Apley, DVM, PhD, DACVCP Department of Clinical Sciences College of Veterinary Medicine Kansas State University Susceptible
More information...CONTINUING MEDICAL EDUCATION...
...CONTINUING MEDICAL EDUCATION...... Drug Resistance and the Treatment of Upper Respiratory Infections GOAL To provide comprehensive and up-to-date information concerning drug resistance and the implications
More informationAntibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
Antimicrobial susceptibility of Shigella, 2015 and 2016 Helen Heffernan and Rosemary Woodhouse Antibiotic Reference Laboratory, Institute of Environmental Science and Research Limited (ESR); August 2017
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More information21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report Antibiotics Review
(1) Have all important studies/evidence of which you are aware been included in the application? Yes No Please provide brief comments on any relevant studies that have not been included: (2) For each of
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationPrinciples of Antimicrobial Therapy
Principles of Antimicrobial Therapy Doo Ryeon Chung, MD, PhD Professor of Medicine, Division of Infectious Diseases Director, Infection Control Office SUNGKYUNKWAN UNIVERSITY SCHOOL OF MEDICINE CASE 1
More informationDecreased susceptibility of penidllid-resistant pnenmococd to twentyfour pmactam antibiotics
Journal of Antimicrobial Chemotherapy (99) 30, 79- Decreased susceptibility of penidllid-resistant pnenmococd to twentyfour pmactam antibiotics J. liriares**, T. Akmstf*, J. L. Perez', J. Ayats*, M A.
More informationReceived 19 December 2005/Returned for modification 22 February 2006/Accepted 3 May 2006
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2006, p. 3346 3351 Vol. 44, No. 9 0095-1137/06/$08.00 0 doi:10.1128/jcm.02631-05 Copyright 2006, American Society for Microbiology. All Rights Reserved. As a Bacterial
More informationPharmacological Evaluation of Amikacin in Neonates
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUlY 1975, p. 86-90 Copyright 0 1975 American Society for Microbiology Vol. 8, No. 1 Printed in U.SA. Pharmacological Evaluation of Amikacin in Neonates JORGE B.
More informationAppropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationEvaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals
J Vet Diagn Invest :164 168 (1998) Evaluation of a computerized antimicrobial susceptibility system with bacteria isolated from animals Susannah K. Hubert, Phouc Dinh Nguyen, Robert D. Walker Abstract.
More informationINCREASING PREVALENCE OF MULTIDRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE IN THE UNITED STATES
INCREASING PREVALENCE OF MULTIDRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE IN THE UNITED STATES INCREASING PREVALENCE OF MULTIDRUG-RESISTANT STREPTOCOCCUS PNEUMONIAE IN THE UNITED STATES CYNTHIA G. WHITNEY,
More informationCentral Nervous System Infections
Central Nervous System Infections Meningitis Treatment Bacterial meningitis is a MEDICAL EMERGENCY. ANTIBIOTICS SHOULD BE STARTED AS SOON AS THE POSSIBILITY OF BACTERIAL MENINGITIS BECOMES EVIDENT, IDEALLY
More informationAPPENDIX III - DOUBLE DISK TEST FOR ESBL
Policy # MI\ANTI\04\03\v03 Page 1 of 5 Section: Antimicrobial Susceptibility Testing Manual Subject Title: Appendix III - Double Disk Test for ESBL Issued by: LABORATORY MANAGER Original Date: January
More informationClinical efficacy of cefpodoxime in respiratory tract infection
Journal of Antimicrobial Chemotherapy (2002) 50, Topic T1, 23 27 DOI: 10.1093/jac/dkf805 Clinical efficacy of cefpodoxime in respiratory tract infection Robert Cohen* Department of Microbiology, Intercommunal
More information6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS
6.0 ANTIBACTERIAL ACTIVITY OF CAROTENOID FROM HALOMONAS SPECIES AGAINST CHOSEN HUMAN BACTERIAL PATHOGENS 6.1 INTRODUCTION Microorganisms that cause infectious disease are called pathogenic microbes. Although
More informationMarc Decramer 3. Respiratory Division, University Hospitals Leuven, Leuven, Belgium
AAC Accepts, published online ahead of print on April 0 Antimicrob. Agents Chemother. doi:./aac.0001- Copyright 0, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.
More informationEUCAST-and CLSI potency NEO-SENSITABS
EUCASTand CLSI potency NEOSENSITABS Neo Sensitabs Page 1 / 6 Document: 6.2.0 Fastidious organisms EUCAST Interpretation zones and MIC breakpoints according to recommendations by the "Comité de l'antibiogramme
More informationa. 379 laboratories provided quantitative results, e.g (DD method) to 35.4% (MIC method) of all participants; see Table 2.
AND QUANTITATIVE PRECISION (SAMPLE UR-01, 2017) Background and Plan of Analysis Sample UR-01 (2017) was sent to API participants as a simulated urine culture for recognition of a significant pathogen colony
More informationIntroduction to Pharmacokinetics and Pharmacodynamics
Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:
More informationBrief reports. Heat stability of the antimicrobial activity of sixty-two antibacterial agents
Journal of Antimicrobial Chemotherapy (5) 35, -5 Brief reports Heat stability of the antimicrobial activity of sixty-two antibacterial agents Walter H. Traub and Birgit Leonhard Institut fur Medizinische
More informationAntibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi
Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What
More informationPrevalence of Drug-Resistant Strains of Streptococcus Pneumoniae in Abakaliki
American Journal of Infectious Diseases, 2012, 8 (3), 123-127 ISSN: 1553-6203 2012 Science Publication doi:10.3844/ajidsp.2012.123.127 Published Online 8 (3) 2012 (http://www.thescipub.com/ajid.toc) Prevalence
More informationEuropean Committee on Antimicrobial Susceptibility Testing
European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01
More informationجداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی
جداول میکروارگانیسم های بیماریزای اولویت دار و آنتی بیوتیک های تعیین شده برای آزمایش تعیین حساسیت ضد میکروبی در برنامه مهار مقاومت میکروبی ویرایش دوم بر اساس ed., 2017 CLSI M100 27 th تابستان ۶۹۳۱ تهیه
More informationDETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY*
44 DETERMINING CORRECT DOSING REGIMENS OF ANTIBIOTICS BASED ON THE THEIR BACTERICIDAL ACTIVITY* AUTHOR: Cecilia C. Maramba-Lazarte, MD, MScID University of the Philippines College of Medicine-Philippine
More information56 Clinical and Laboratory Standards Institute. All rights reserved.
Table 2C 56 Clinical and Laboratory Standards Institute. All rights reserved. Table 2C. Zone Diameter and Minimal Inhibitory Concentration Breakpoints for Testing Conditions Medium: Inoculum: diffusion:
More information